重复给予度洛西汀通过脊髓去甲肾上腺素累积效应抑制神经病理性疼痛
该研究在大鼠脊髓神经结扎(SNL)6周后模型上,连续3天皮下注射度洛西汀(10 mg/kg/天),发现其可减轻机械性痛觉过敏并恢复受损的痛觉刺激诱发镇痛(NSIA),同时增加脊髓背角去甲肾上腺素含量;鞘内注射α2肾上腺素受体拮抗剂可逆转上述效应。
要点
- 连续3天度洛西汀可减轻SNL大鼠机械性痛觉过敏并恢复NSIA。
- 度洛西汀增加脊髓背角去甲肾上腺素含量,鞘内α2拮抗剂可逆转其效应。
- 度洛西汀未改变辣椒素诱发的脊髓去甲肾上腺素释放或蓝斑磷酸化CREB阳性细胞比例。
核心结论
- 连续3天注射度洛西汀可抑制SNL大鼠的痛觉过敏并恢复受损的NSIA,其效应依赖于脊髓去甲肾上腺素下行抑制系统的恢复。
研究设计与样本
- 研究使用SNL大鼠模型,在术后6周连续3天皮下注射度洛西汀(10 mg/kg/天),并评估行为学超敏、NSIA、脊髓微透析、去甲肾上腺素含量及蓝斑免疫组化。
主要发现
- SNL大鼠第4天机械性痛觉过敏阈值:溶媒组88 ± 9.4 g vs 度洛西汀组148 ± 13 g,P < .001,估计治疗效应65(95%CI 50.6-79.4),每组n=6。
- 注射后30分钟NSIA:溶媒组154 ± 10 g vs 度洛西汀组213 ± 33 g,P < .001,估计治疗效应71.3(95%CI 57.4-85.2),每组n=6。
- 脊髓背角去甲肾上腺素含量同侧:溶媒组946.7 ± 203.6 pg/g vs 度洛西汀组1593.5 ± 181.4 pg/g,P < .001,差值646.79 pg/g(95%CI 481.61-811.97)。
- 对侧去甲肾上腺素含量:溶媒组845.0 ± 164.7 pg/g vs 度洛西汀组1557.2 ± 237.4 pg/g,P < .001,差值712.17 pg/g(95%CI 449.31-975.02)。
- 鞘内注射α2拮抗剂idazoxan后,度洛西汀的抗痛觉过敏效应被逆转(注射前133 ± 5.7 g vs 注射后30分钟85.8 ± 6.5 g,P < .001,差值-47,95%CI -39.1至-54.8,每组n=6),NSIA亦被逆转(溶媒鞘内组219 ± 7.4 g vs idazoxan鞘内组153 ± 10 g,P < .001,差值-65.8 g,95%CI -25.2至-77.4,每组n=6)。
临床怎么用
- 度洛西汀的镇痛作用可能与恢复脊髓去甲肾上腺素下行抑制系统有关,α2受体拮抗可逆转其效应。
局限性
- 研究为大鼠SNL模型,样本量每组n=6,结果需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antidepressants are used to treat neuropathic pain and although the detailed mechanisms of their effects are unclear, the descending noradrenergic inhibitory system might play an important role. We tested our hypothesis that repeated administration of duloxetine suppresses neuropathic pain by restoring the descending noradrenergic inhibitory system in rats 6 weeks after spinal nerve ligation (SNL). METHODS: We subcutaneously injected SNL rats with duloxetine (10 mg kg day) daily for 3 consecutive days and assessed behavioral hypersensitivity and noxious stimulus-induced analgesia (NSIA) activated by subcutaneous injection of capsaicin. We also performed microdialysis studies of the spinal cord, noradrenaline measurements of homogenized lumbar spinal tissue, and immunohistochemistry of the locus coeruleus. RESULTS: Three daily injections of duloxetine attenuated the mechanical hyperalgesia induced by SNL (SNL treated with vehicle: 88 ± 9.4 g versus SNL treated with duloxetine: 148 ± 13 g, P < .001; estimated treatment effect of duloxetine [95% confidence interval {CI}], 65 [50.6-79.4]; n = 6/group, on day 4) and recovered the decreased NSIA (vehicle: 154 ± 10 g versus duloxetine: 213 ± 33 g, P < .001; 71.3 [57.4-85.2]; n = 6/group, 30 minutes after injection). The noradrenaline content in the dorsal spinal cord increased bilaterally (SNL treated with vehicle: 946.7 ± 203.6 pg/g versus SNL treated with duloxetine: 1593.5 ± 181.4 pg/g, P < .001; 646.79 pg/g [481.61-811.97] on the ipsilateral side; SNL treated with vehicle: 845.0 ± 164.7 pg/g versus SNL treated with vehicle: 1557.2 ± 237.4 pg/g, P < .001; 712.17 pg/g [449.31-975.02] on the contralateral side). Intrathecal injection (IT) of the α2-adrenoceptor antagonist idazoxan reversed both the antihyperalgesic effect (before IT: 133 ± 5.7 g versus 30 minutes after IT: 85.8 ± 6.5 g, P < .001, -47 [-39.1 to -54.8], n = 6/group, and NSIA; vehicle-IT: 219 ± 7.4 g versus idazoxan-IT: 153 ± 10 g, P < .001; -65.8 g [-25.2 to -77.4] n = 6/group, 30 minutes after forepaw injection of capsaicin). Duloxetine treatment did not alter the noradrenaline release in the spinal cord after capsaicin injection (P = .415), or the fraction of nuclei positive for phosphorylated cyclic adenosine monophosphate response element binding protein in the locus coeruleus (P = 1.00 duloxetine versus vehicle 120 minutes after forepaw injection of vehicle and P = 1.00 duloxetine versus vehicle 120 minutes after forepaw injection of capsaicin). CONCLUSIONS: These findings suggest that 3 daily injections of duloxetine suppressed hyperalgesia and recovered impaired NSIA in rats 6 weeks after nerve injury. Both effects of duloxetine were reversed by IT of an α2-adrenoceptor antagonist. These findings suggest the inhibitory effects of duloxetine against neuropathic pain depend on recovery of the noradrenergic descending inhibitory system, especially in the spinal cord.
引用
- Ito S, Suto T, Saito S, et al. Repeated Administration of Duloxetine Suppresses Neuropathic Pain by Accumulating Effects of Noradrenaline in the Spinal Cord. Anesth Analg. 2018. PMID: 28787337. doi:10.1213/ANE.0000000000002380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。